代表性论文：

1. Meng Y, Lin Y, Luo Z, Tan X, Yu X, Ren H, Cheng Q, Fang C, Wei T*. Fusion Peptide-Incorporated Lipid Nanoparticles Boost Endosomal Escape and Enhance Cytosolic mRNA Delivery. Adv Mater. 2026, doi: 10.1002/adma.202515130.
2. Du H#,, You X#,, Zhang J, Liu S, Zhou Y, Wang Y, Yang C, Meng Y, Liu X, Zhang H, Li Y, Shen J, Yuan H, Xu P, He C, Xiao Y, Gao Z, Zang J, Wei T*, Song M*. CAR Macrophages Engineered In Vivo for Attenuating Myocardial Ischemia-Reperfusion Injury. Circ Res. 2025, 137(6):846-859.
3. Lin Y#, Li M#, Luo Z, Meng Y, Zong Y, Ren H, Yu X, Tan X, Liu F, Wei T*, Cheng Q*. Tissue-specific mRNA delivery and prime editing with peptide–ionizable lipid nanoparticles. Nat Mater. 2025, doi:10.1038/s41563-025-02320-9.
4. Ren H, Yu X, Li M, Luo Z, Lin Y, Meng Y, Cheng Q*, Wei T*. Nebulized Lipid Nanoparticles Deliver mRNA to the Liver for Treatment of Metabolic Diseases. Nano Lett. 2025, doi: 10.1021/acs.nanolett.5c03184.
5. Li M#, Lin Y#, Cheng Q*, Wei T*. Prime Editing: A Revolutionary Technology for Precise Treatment of Genetic Disorders. Cell Prolif. 2025, 58(4):e13808.
6. Luo Z, Lin Y, Meng Y, Li M, Ren H, Shi H, Cheng Q*, Wei T*. Spleen-Targeted mRNA Vaccine Doped with Manganese Adjuvant for Robust Anticancer Immunity In Vivo. ACS Nano. 2024, 18 (44):30701-30715.
7. Fei Y#, Yu X#, Liu P, Ren H, Wei T*, Cheng Q*. Simplified Lipid Nanoparticles for Tissue- And Cell-Targeted mRNA Delivery Facilitate Precision Tumor Therapy in a Lung Metastasis Mouse Model. Adv Mater. 2024, 36 (48):2409812.
8. Zong Y, Lin Y, Wei T*, Cheng Q*. Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy. Adv Mater. 2023, 35(51):e2303261.
9. Wei T#, Sun Y#, Cheng Q#, Chatterjee S, Traylor Z, Johnson LT, Coquelin ML, Wang J, Torres MJ, Lian X, Wang X, Xiao Y, Hodges CA, Siegwart DJ. Lung SORT LNPs enable precise homology-directed repair mediated CRISPR/Cas genome correction in cystic fibrosis models. Nat Commun. 2023, 14(1):7322.
10. Wei T#, Cheng Q#, Min YL, Olson EN, Siegwart DJ*. Systemic nanoparticle delivery of CRISPR/Cas9 ribonucleoproteins for effective tissue-specific genome editing. Nat Commun. 2020, 11(1):3232.
11. Cheng Q#, Wei T#, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ*. Selective ORgan Targeting (SORT) nanoparticles for tissue specific mRNA delivery and CRISPR/Cas gene editing. Nat Nanotechnol. 2020, 15(4):313.

（#共同第一作者, *通讯作者）

代表性专利（选填）：

1. 魏妥，饶书权，姚瑶，罗自金，杜晶晶. 抗体修饰的脂质纳米颗粒及其制备方法和作为靶向载体的应用（中国申请号：202511420633.2；申请日期：2025/9/30）
2. 魏妥，程强，王秋. 一种氢键辅助的两组分脂质纳米粒及其制备方法与应用（中国申请号：2025112913095；申请日期：2025/9/10）
3. 宋默识，杜恒，魏妥. 治疗心肌缺血再灌注损伤或心肌梗死的药物及其所用表达嵌合抗原受体的重组细胞（中国申请号：CN202510610789.0；申请日期：2025/05/13）
4. 魏妥，程强，林艺. 胸腺靶向肽基可离子化脂质及其纳米颗粒（中国申请号：2025102383020；申请日期：2025/2/28）
5. 魏妥，任红玉. 一种靶向组织的雾化吸入型脂质纳米颗粒及其递送方法与应用（中国申请号：2024119126842；申请日期：2024/12/24）
6. 魏妥，罗自金. 一种掺杂金属离子佐剂的脾脏靶向 mRNA 疫苗及其制备方法与应用（中国申请号：2024110561345；申请日期：2024/08/02）
7. 程强，魏妥，林艺，李梦尧. 肽基可离子化脂质合成及其应用（PCT申请号：PCT/CN2024/104390；申请日期：2024/07/09）
8. 程强，魏妥，费圆，于晓璐. 脂质纳米颗粒及其应用（申请号：2023110328168；申请日期： 2023/08/16）
9. Siegwart DJ, Wei T, Cheng Q and Torres M. Compositions, Methods and Uses for Treating Cystic Fibrosis and Related Disorders. (Application number: PCT/US2022/023333, Application Date: 2022/04/04)
10. Torres M, Siegwart DJ, Eby J, Bhattacharjee R, Wustman B, Kharitonov V, Cheng Q and Wei T. Compositions and methods for targeted delivery to cells. (Application number: PCT/US2022/021176, Application Date: 2022/03/21)
11. Siegwart DJ, Liu S, Yu X, Cheng Q and Wei T. Functional ionizable phospholipids (Application number: PCT/US2021/047203, Application Date: 2021/08/23)
12. Cheng Q, Wei T and Siegwart DJ. Compositions and methods for organ specific delivery of nucleic acids (Application number: PCT/US2019/049552, Application Date: 2019/09/04, licensed)
13. Cheng Q, Wei T and Siegwart DJ. Compositions and methods for organ specific delivery of nucleic acids (Application number: PCT/US2019/049565, Application Date: 2019/09/04, licensed)
14. Liang X-J, Ma H, Liu J, Wei T. Nucleic acid, drug carrier, pharmaceutical composition and preparation method of drug carrier and pharmaceutical composition. (Application number: CN201110421565.3A, Granted Date: 2014/09/24)